Selective Inhibition of Cysteine-Dependent Enzymes by Bioorthogonal Tethering

[Display omitted] •Rapid and selective inhibition of cysteine-dependent enzymes is often challenging.•We showed this can be achieved by bioorthogonal tethering of an electrophile.•Selective inhibition of two E2 enzymes was demonstrated.•The technique developed here represents a valuable biomedical t...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of molecular biology 2022-04, Vol.434 (8), p.167524-167524, Article 167524
Hauptverfasser: Spear, Luke A., Huang, Yang, Chen, Jinghao, Nödling, Alexander R., Virdee, Satpal, Tsai, Yu-Hsuan
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:[Display omitted] •Rapid and selective inhibition of cysteine-dependent enzymes is often challenging.•We showed this can be achieved by bioorthogonal tethering of an electrophile.•Selective inhibition of two E2 enzymes was demonstrated.•The technique developed here represents a valuable biomedical tool. A general approach for the rapid and selective inhibition of enzymes in cells using a common tool compound would be of great value for research and therapeutic development. We previously reported a chemogenetic strategy that addresses this challenge for kinases, relying on bioorthogonal tethering of a pan inhibitor to a target kinase through a genetically encoded non-canonical amino acid. However, pan inhibitors are not available for many enzyme classes. Here, we expand the scope of the chemogenetic strategy to cysteine-dependent enzymes by bioorthogonal tethering of electrophilic warheads. For proof of concept, selective inhibition of two E2 ubiquitin-conjugating enzymes, UBE2L3 and UBE2D1, was demonstrated in biochemical assays. Further development and optimization of this approach should enable its use in cells as well as with other cysteine-dependent enzymes, facilitating the investigation of their cellular function and validation as therapeutic targets.
ISSN:0022-2836
1089-8638
DOI:10.1016/j.jmb.2022.167524